The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
The impact of short-chain fatty acids on GLP-1 and PYY secretion from the isolated perfused rat colon
Open accessAbstract
The colonic epithelium harbors a large number of endocrine cells, but little is known about the endocrine functions of the colon. However, the high density of glucagon like peptide-1 (GLP-1)- and peptide-YY (PYY)-secreting L cells is of great interest because of the potential antidiabetic and antiobesity effects of GLP-1 and PYY. Short-chain fatty acids (SCFAs) produced by local bacterial fermentation are suggested to activate the colonic free fatty acid receptors FFAR2 (GPR43) and FFAR3 (GPR41), stimulating the colonic L cells. We used the isolated perfused rat colon as a model of colonic endocrine secretion and studied the effects of the predominant SCFAs formed: acetate, propionate, and butyrate. We show that luminal and especially vascular infusion of acetate and butyrate significantly increases colonic GLP-1 secretion, and to a minor extent also PYY secretion, but only after enhancement of intracellular cAMP. Propionate neither affected GLP-1 nor PYY secretion whether administered luminally or vascularly. A FFAR2- and FFAR3–specific agonist [( S)-2-(4-chlorophenyl)-3,3-dimethyl- N-(5-phenylthiazol-2-yl)butamide (CFMB)/ AR420626 ] had no effect on colonic GLP-1 output, and a FFAR3 antagonist ( AR399519 ) did not decrease the SCFA-induced GLP-1 response. However, the voltage-gated Ca 2+-channel blocker nifedipine, the K ATP-channel opener diazoxide, and the ATP synthesis inhibitor 2,4-dinitrophenol completely abolished the responses. FFAR2 receptor studies confirmed low-potent partial agonism of acetate, propionate, and butyrate, compared with CFMB, which is a full agonist with ~750-fold higher potency than the SCFAs. In conclusion, SCFAs may increase colonic GLP-1/PYY secretion, but FFAR2/FFAR3 do not seem to be involved. Rather, SCFAs are metabolized and appear to function as a colonocyte energy source. NEW & NOTEWORTHY By the use of in situ isolated perfused rat colon we show that short-chain fatty acids (SCFAs) primarily are used as a colonocyte energy source in the rat, subsequently triggering glucagon like peptide-1 (GLP-1) secretion independent of the free fatty acid receptors FFAR2 and FFAR3. Opposite many previous studies on SCFAs and FFAR2/FFAR3 and GLP-1 secretion, this experimental model allows investigation of the physiological interactions between luminal nutrients and secretion from cells whose function depend critically on their blood supply as well as nerve and paracrine interactions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
den Besten, G., van Eunen, K., Groen, A. K., Venema, K., Reijngoud, D.-J., & Bakker, B. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.r036012 · Cited by 5,048
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Self-citationShort chain fatty acids in human large intestine, portal, hepatic and venous blood
Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., & Macfarlane, G. T. (1987) · Gut · doi:10.1136/gut.28.10.1221 · Cited by 3,119
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
Brown, A. J., Goldsworthy, S. M., Barnes, A. A., Eilert, M. M., Tcheang, L., Daniels, D., Muir, A. I., Wigglesworth, M. J., Kinghorn, I., Fraser, N. J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211609200 · Cited by 2,409
Tolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404
Regulation of short-chain fatty acid production
Macfarlane, S., & Macfarlane, G. T. (2003) · Proceedings of the Nutrition Society · doi:10.1079/pns2002207 · Cited by 1,939
Le Poul, E., Loison, C., Struyf, S., Springael, J.-Y., Lannoy, V., Decobecq, M.-E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301403200 · Cited by 1,651
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“Through secretion of GLP-1 and PYY, SCFAs may indirectly affect host metabolism by increasing satiety and decreasing gastric emptying and gut motility (25, 47).”
BackgroundSelf-citationLin, H. V., Frassetto, A., Kowalik Jr, E. J., Nawrocki, A. R., Lu, M. M., Kosinski, J. R., Hubert, J. A., Szeto, D., Yao, X., Forrest, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035240 · Cited by 1,378
Cited by
Free Fatty Acid Receptors in Health and Disease
Kimura, I., Ichimura, A., Ohue-Kitano, R., & Igarashi, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00041.2018 · Cited by 1,018
Short-chain fatty acids in diseases
Zhang, D., Jian, Y.-P., Zhang, Y.-N., Li, Y., Gu, L.-T., Sun, H.-H., Liu, M.-D., Zhou, H.-L., Wang, Y.-S., & Xu, Z.-X. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01219-9 · Cited by 718
Function and mechanisms of enteroendocrine cells and gut hormones in metabolism
Gribble, F. M., & Reimann, F. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0168-8 · Cited by 670
Clostridium species as probiotics: potentials and challenges
Guo, P., Zhang, K., Ma, X., & He, P. (2020) · Journal of Animal Science and Biotechnology · doi:10.1186/s40104-019-0402-1 · Cited by 597
Meslier, V., Laiola, M., Roager, H. M., De Filippis, F., Roume, H., Quinquis, B., Giacco, R., Mennella, I., Ferracane, R., Pons, N., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-320438 · Cited by 583
Microbiota-derived metabolites as drivers of gut–brain communication
Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N., & Hanhineva, K. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2102878 · Cited by 462
Role of microbiota-derived short-chain fatty acids in nervous system disorders
Mirzaei, R., Bouzari, B., Hosseini-Fard, S. R., Mazaheri, M., Ahmadyousefi, Y., Abdi, M., Jalalifar, S., Karimitabar, Z., Teimoori, A., Keyvani, H., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111661 · Cited by 386
Facchin, S., Bertin, L., Bonazzi, E., Lorenzon, G., De Barba, C., Barberio, B., Zingone, F., Maniero, D., Scarpa, M., Ruffolo, C., et al. (2024) · Life · doi:10.3390/life14050559 · Cited by 380
Butyrate in Energy Metabolism: There Is Still More to Learn
Zhang, L., Liu, C., Jiang, Q., & Yin, Y. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.12.003 · Cited by 364
Gut microbiome and its role in obesity and insulin resistance
Lee, C. J., Sears, C. L., & Maruthur, N. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14107 · Cited by 350
Müller, M., Hernández, M. A. G., Goossens, G. H., Reijnders, D., Holst, J. J., Jocken, J. W. E., van Eijk, H., Canfora, E. E., & Blaak, E. E. (2019) · Scientific Reports · doi:10.1038/s41598-019-48775-0 · Cited by 324
Self-citationRole of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
The Protective Role of Butyrate against Obesity and Obesity-Related Diseases
Coppola, S., Avagliano, C., Calignano, A., & Berni Canani, R. (2021) · Molecules · doi:10.3390/molecules26030682 · Cited by 261
The function of gut microbiota in immune-related neurological disorders: a review
Sittipo, P., Choi, J., Lee, S., & Lee, Y. K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02510-1 · Cited by 221
Metabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Probiotics and prebiotics for the amelioration of type 1 diabetes: Present and future perspectives
Mishra, S., Wang, S., Nagpal, R., Miller, B., Singh, R., Taraphder, S., & Yadav, H. (2019) · Microorganisms · doi:10.3390/microorganisms7030067 · Cited by 131
“In the lower intestine of humans [96] and rats [71,96], prebiotics could be particularly important for the production of SCFAs, which act as ligands for several GPCRs, such as FFAR2 and FFAR3.”
BackgroundGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“Colonic fermentation products may play a role 24 , but it is difficult to relate the occurrence of fermentation 22 to the diurnal plasma concentration profile of GLP-1 (or GLP-2 for that matter).”
Self-citationGLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Masse, K. E., & Lu, V. B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1169624 · Cited by 120
“A study found that the selective FFA3 agonist, AR420626, promoted GLP-1 release from primary colonic cultures (88) and perfused intact colons (103).”
BackgroundReappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
The Emerging Role of Polyphenols in the Management of Type 2 Diabetes
Wang, Y., Alkhalidy, H., & Liu, D. (2021) · Molecules · doi:10.3390/molecules26030703 · Cited by 88
Ducastel, S., Touche, V., Trabelsi, M.-S., Boulinguiez, A., Butruille, L., Nawrot, M., Peschard, S., Chávez-Talavera, O., Dorchies, E., Vallez, E., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56743-x · Cited by 84
Dietary Management of Obesity: A Review of the Evidence
Hwalla, N., & Jaafar, Z. (2020) · Diagnostics · doi:10.3390/diagnostics11010024 · Cited by 66
Selective stimulation of colonic L cells improves metabolic outcomes in mice
Lewis, J. E., Miedzybrodzka, E. L., Foreman, R. E., Woodward, O. R. M., Kay, R. G., Goldspink, D. A., Gribble, F. M., & Reimann, F. (2020) · Diabetologia · doi:10.1007/s00125-020-05149-w · Cited by 59
Incretin Hormones, Obesity and Gut Microbiota
Angelini, G., Russo, S., & Mingrone, G. (2024) · Peptides · doi:10.1016/j.peptides.2024.171216 · Cited by 47
Qin, W., Ying, W., Hamaker, B., & Zhang, G. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12808 · Cited by 48
Monnier, L., Schlienger, J.-L., Colette, C., & Bonnet, F. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.002 · Cited by 47
Kao, A. C.-C., Chan, K. W., Anthony, D. C., Lennox, B. R., & Burnet, P. W. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.014 · Cited by 32
Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29
Gut Microbiota Restores Central Neuropeptide Deficits in Germ-Free Mice
Hamamah, S., & Covasa, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911756 · Cited by 25
Wu, W., Chen, Z., Han, J., Qian, L., Wang, W., Lei, J., & Wang, H. (2023) · Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity · doi:10.1007/s40519-023-01593-w · Cited by 18
“Various studies performed using the mouse model explained the mechanism of propionic acid in preventing obesity by inhibiting food intake, increasing insulin sensitivity, and energy expenditure [145, 153, 158].”
BackgroundInfluential
Metadata
- Authors
- Christiansen, C. B., Gabe, M. B. N., Svendsen, B., Dragsted, L. O., Rosenkilde, M. M., & Holst, J. J.
- Venue
- American Journal of Physiology-Gastrointestinal and Liver Physiology
- Publisher
- American Physiological Society
- Published
- 2018-07-01
- Volume
- 315
- Issue
- 1
- Pages
- G53-G65
- ISSN
- 0193-1857 (ISSN-L)
- 1522-1547
- OpenAlex
- W2793376305
- Cited by
- 401
- References
- 69
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.